TICKERNERD
Menu
PACBPACBHealthcare · Medical Devices

PACB Stock Forecast: Pacific Biosciences of California, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.35
+9.76% on the day

The 7 Wall Street analysts covering Pacific Biosciences of California, Inc. hold a median 12-month price target of $2.5 — +85.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$419.6M
Ticker Nerd rank
43 / 100
Median analyst target
$2.50
Analysts covering
7
Total return, dividends reinvested
1W
+17.4%
1M
−3.6%
YTD
−27.8%
1Y
+7.1%
From 52W high
−49.4%
From 52W low
+21.6%
$1.11
$2.67
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PACB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pacific Biosciences of California, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
43 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
96
Size
56
Quality
56
Accruals
55
Value
44
Momentum
41
Volatility
38
Revisions
31
Issuance
30

Growth (96): Sales and profits are climbing, and climbing faster than before.

Issuance (30): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PACB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PACB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$1.50$2.00$2.50$3.00Oct 25Jan 26Apr 26Jul 26PACBHigh $3.00Median $2.50Low $1.25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
4 Buy2 Hold1 Sell
Low $1.25Median $2.50High $3.00

The green dot is the last close — the median target sits +85.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 May 2026BarclaysMaintainsUnderweight$1.00 → $1.50
14 Apr 2026BarclaysMaintainsUnderweight—
6 Mar 2026BarclaysDowngradeUnderweight—
15 Dec 2025BarclaysMaintainsEqual-Weight—
11 Nov 2025Piper SandlerMaintainsNeutral—
10 Nov 2025Stephens & Co.MaintainsOverweight—
11 Aug 2025Piper SandlerMaintainsNeutral—
25 June 2025BarclaysMaintainsEqual-Weight—
15 May 2025Piper SandlerMaintainsNeutral—
15 May 2025Stephens & Co.ReiteratesOverweight—
10 Apr 2025Canaccord GenuityMaintainsBuy—
25 Mar 2025ScotiabankMaintainsSector Outperform—
20 Feb 2025Piper SandlerReiteratesNeutral—
18 Feb 2025Goldman SachsMaintainsNeutral—
18 Feb 2025Stephens & Co.ReiteratesOverweight—
14 Feb 2025Stephens & Co.ReiteratesOverweight—
23 Jan 2025Goldman SachsMaintainsNeutral—
11 Nov 2024Piper SandlerMaintainsNeutral—
11 Nov 2024ScotiabankMaintainsSector Outperform—
11 Nov 2024UBSDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PACB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PACB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Pacific Biosciences of California, Inc. (PACB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.8×

Cheaper than 81% of US stocks

Price / sales
2.6×

Cheaper than 47% of US stocks

Price / book
−12.8×

Cheaper than 98% of US stocks

EV / EBITDA
4.5×

Cheaper than 54% of US stocks

Growth & margins
Revenue growth (YoY)
−1.9%

Higher than 24% of US stocks

Earnings growth (YoY)
−1.9%

Higher than 34% of US stocks

Gross margin
32.4%

Higher than 38% of US stocks

Operating margin
−114.4%

Higher than 13% of US stocks

Net margin
−82.5%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−929.3%

Higher than 2% of US stocks

Return on assets
−14.1%

Higher than 23% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PACB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
PACBPacific Biosciences of California, Inc.$419.6M
43
OFIXOrthofix Medical, Inc.$396.4M
81
MASS908 Devices, Inc.$438.2M
84
CATXPerspective Therapeutics, Inc.$375.9M
30
SGHTSight Sciences, Inc.$446.1M
86
CLPTClearpoint Neuro, Inc.$457.8M
20
SIShoulder Innovations, Inc.$459.3M
18

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pacific Biosciences of California, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PACB news & analysis

PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity

MarketBeat · 16 Aug 2026negative

PacBio cut its outlook as the transition to its SPRQ-Nx chemistry slows, and set a target of reaching cash-flow positivity by 2028. The company reported second-quarter revenue of $39 million, comprising $20 million in consumables, $13 million in instrument and $6 million in services revenue.

Why it matters — PACB watchers would care because the lowered guidance and slower SPRQ-Nx transition signal near-term headwinds, while the 2028 cash-flow target offers a longer-term financial milestone for the company.

PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut

Zacks Investment Research · 6 Aug 2026negative

PacBio matched earnings estimates in Q2 but missed revenue expectations as sales fell 2%, and the company lowered its 2026 revenue outlook.

Why it matters — A lower 2026 revenue forecast and a sales decline, particularly from weak instrument and Asia-Pacific performance, signal headwinds in PacBio's growth trajectory.

Pacific Biosciences: It's Only Getting Worse

Seeking Alpha · 6 Aug 2026negative

Pacific Biosciences reported Q2 revenues of $39.01 million, missing estimates, and guided 2026 revenues below consensus. Operating and net losses remain sizable, with cash under $237 million and nearly $645 million in debt outstanding, while the stock trades at 2.4x expected 2026 revenues, a steep discount to peers.

Why it matters — A PACB watcher would care because the company missed revenue estimates, lowered its 2026 revenue guidance, and continues to carry large losses and substantial debt that weigh on its financial outlook.

Pacific Biosciences of California, Inc. (PACB) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Pacific Biosciences of California, Inc. (PACB) held its Q2 2026 earnings call, and a transcript of the call has been published by Seeking Alpha. The item is a transcript of the company's quarterly earnings discussion, as presented on the site.

Why it matters — A PACB watcher would care because the earnings call transcript provides the company's own commentary and figures from its Q2 2026 financial results.

Pacific Biosciences of California Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026negative

Pacific Biosciences reported second-quarter 2026 revenue of about $39 million, roughly flat from $39.8 million a year earlier. The company also announced an immediate leadership transition and lowered its full-year revenue outlook, citing a slower-than-expected rollout of its new multi-use sequencing chemistry and ongoing funding constraints in academic and government markets.

Why it matters — PACB watchers would note the lowered full-year guidance, leadership change, and slower commercial uptake of the new chemistry as signals about near-term growth prospects for the company.

FAQ

Frequently asked questions about PACB stock

What is the PACB stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Pacific Biosciences of California, Inc. have a median 12-month price target of $2.5, with estimates ranging from $1.25 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PACB stock a buy right now?

Of the 7 analysts covering Pacific Biosciences of California, Inc., 4 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Pacific Biosciences of California, Inc. 43 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PACB?

As at 22 Aug 2026, Pacific Biosciences of California, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).

Will PACB stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +85.2% from the last close, and Ticker Nerd's factor model ranks Pacific Biosciences of California, Inc. 43 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PACB stock forecast for 2030?

No analyst covering Pacific Biosciences of California, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PACB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.25 to $3 over the next 12 months.

How has PACB stock performed over the past year?

Pacific Biosciences of California, Inc. returned +7.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pacific Biosciences of California, Inc. do?

Pacific Biosciences of California, Inc. is a biotechnology company that develops, manufactures, and markets advanced DNA sequencing systems for genetic analysis.

What is the latest news on PACB?

The most recent item we track (MarketBeat, 16 Aug 2026): "PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity". PacBio cut its outlook as the transition to its SPRQ-Nx chemistry slows, and set a target of reaching cash-flow positivity by 2028. The company reported second-quarter revenue of $39 million, comprising $20 million in consumables, $13 million in instrument and $6 million in services revenue.

Company

About Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc. is a biotechnology company that develops, manufactures, and markets advanced DNA sequencing systems for genetic analysis. The company focuses on high-accuracy long-read and complementary short-read sequencing technologies that enable comprehensive characterization of genomes, transcriptomes, and epigenomes. Its product portfolio includes sequencing instruments such as the Revio and Onso systems, along with consumables and software that support end-to-end workflows from sample preparation through data analysis. Pacific Biosciences’ platforms are used by academic and governmental research institutions, pharmaceutical and biotechnology companies, agricultural organizations, and clinical research groups for applications in human genetics, oncology, infectious disease, and plant and animal genomics. The company operates a razor-and-blade business model, generating revenue from both instrument sales and recurring consumable usage. Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences plays a notable role in the genomics market by providing tools designed to resolve genetically complex problems and deliver highly detailed views of genetic variation.

CEO Mr. Mark Van Oene Ph.D. · 485 employees · United States · https://www.pacb.com